PMID- 27839924
OWN - NLM
STAT- MEDLINE
DCOM- 20180214
LR  - 20181009
IS  - 1873-460X (Electronic)
IS  - 1056-8727 (Linking)
VI  - 31
IP  - 1
DP  - 2017 Jan
TI  - The U-shaped relationship between fibroblast growth factor 21 and microvascular 
      complication in type 2 diabetes mellitus.
PG  - 134-140
LID - S1056-8727(16)30730-9 [pii]
LID - 10.1016/j.jdiacomp.2016.10.017 [doi]
AB  - AIMS: The aim of this study was to investigate the relationship between serum 
      FGF21 level and all microvascular complication including cardiac autonomic 
      neuropathy (CAN) in patients with type 2 diabetes mellitus (T2DM). METHODS: A 
      total 227 T2DM patients were enrolled and serum FGF21 levels were assessed. 
      Diabetic retinopathy, nephropathy, peripheral neuropathy (DPN), and CAN were 
      evaluated. RESULTS: The prevalence of retinopathy and nephropathy among the FGF21 
      tertiles was significantly different (p=0.001, p=0.006, respectively), whereas no 
      difference was found in the prevalence of DPN and CAN. In multivariate analysis, 
      the odds ratio (OR) for the presence of retinopathy was 0.08 for the FGF21 second 
      tertile when compared with the first tertile (p=0.029). OR of retinopathy in 
      third tertile group was lower than first tertile and higher than second tertile, 
      but statistically insignificant. Crude OR for nephropathy was 0.34 for the second 
      FGF21 tertile, when compared with the first tertile (p=0.015). However, FGF21 
      level was not significantly associated with nephropathy after multivariable 
      adjustment. CONCLUSIONS: In the present study, there was no association between 
      diabetic nephropathy, DPN, and CAN and serum FGF21 levels. However, we found a 
      U-shaped relationship between both lower and higher serum FGF21 levels and 
      diabetic retinopathy. This result suggests that the very low serum FGF21 level 
      itself may associate with diabetic retinopathy and also relatively elevated serum 
      FGF21 level may be a compensatory increase to protect against microvascular 
      injury.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Jung, Chan-Hee
AU  - Jung CH
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Soonchunhyang University College of Medicine, Bucheon Hospital, Republic of 
      Korea.
FAU - Jung, Sang-Hee
AU  - Jung SH
AD  - Department of Obstetrics and Gynecology, Cha University School of Medicine, 
      Bundang Hospital, Republic of Korea.
FAU - Kim, Bo-Yeon
AU  - Kim BY
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Soonchunhyang University College of Medicine, Bucheon Hospital, Republic of 
      Korea.
FAU - Kim, Chul-Hee
AU  - Kim CH
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Soonchunhyang University College of Medicine, Bucheon Hospital, Republic of 
      Korea.
FAU - Kang, Sung-Koo
AU  - Kang SK
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Soonchunhyang University College of Medicine, Bucheon Hospital, Republic of 
      Korea.
FAU - Mok, Ji-Oh
AU  - Mok JO
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Soonchunhyang University College of Medicine, Bucheon Hospital, Republic of 
      Korea. Electronic address: hanna@schmc.ac.kr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20161019
PL  - United States
TA  - J Diabetes Complications
JT  - Journal of diabetes and its complications
JID - 9204583
RN  - 0 (fibroblast growth factor 21)
RN  - 62031-54-3 (Fibroblast Growth Factors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Diabetes Mellitus, Type 2/*blood/*complications/epidemiology
MH  - Diabetic Angiopathies/*blood/epidemiology
MH  - Diabetic Nephropathies/blood/epidemiology
MH  - Diabetic Retinopathy/blood/epidemiology
MH  - Female
MH  - Fibroblast Growth Factors/*blood
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Odds Ratio
OTO - NOTNLM
OT  - Cardiac autonomic neuropathy
OT  - Fibroblast growth factor 21
OT  - Nephropathy
OT  - Neuropathy
OT  - Retinopathy
OT  - Type 2 diabetes mellitus
EDAT- 2016/11/15 06:00
MHDA- 2018/02/15 06:00
CRDT- 2016/11/15 06:00
PHST- 2016/04/15 00:00 [received]
PHST- 2016/10/07 00:00 [revised]
PHST- 2016/10/16 00:00 [accepted]
PHST- 2016/11/15 06:00 [pubmed]
PHST- 2018/02/15 06:00 [medline]
PHST- 2016/11/15 06:00 [entrez]
AID - S1056-8727(16)30730-9 [pii]
AID - 10.1016/j.jdiacomp.2016.10.017 [doi]
PST - ppublish
SO  - J Diabetes Complications. 2017 Jan;31(1):134-140. doi: 
      10.1016/j.jdiacomp.2016.10.017. Epub 2016 Oct 19.